The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow ...

Pfizer has named chief oncology officer Dr Chris Boshoff to the new role of chief of R&D, as the company faces down criticism of its recent efforts to develop and build its pipeline. He is ...

In mid-2024, the commercial president of Pfizer’s oncology unit Suneet Varma announced his retirement after 15 years with the ...

With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.

US pharma giant Pfizer (NYSE: PFE) today announced that Jeffrey Legos will join the company as chief oncology officer.

Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca ...

Pfizer Inc. has announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr.

Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...